Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03461861 · ClinicalTrials.gov registry record · Phase 2
Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
A Phase 2 study of Apoe 4, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT03461861: Completed Phase 2 study of Apoe 4, sponsored by Medical College of Wisconsin.
NCT03461861 is a Phase 2 study of Apoe 4 that has completed, run by Medical College of Wisconsin. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03461861, a Phase 2 study of Apoe 4, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults. The investigators will compare the functional connectivity results after taking AGB101 or placebo.
Primary Outcome
The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AGB101 220 mg
Study Locations (1)
Wisconsin
- Froedtert & The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-04-11 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
What the finished NCT03461861 record still lists
NCT03461861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Apoe 4 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03461861 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03461861 about?
NCT03461861 is a clinical study titled "Network-Level Mechanisms for Preclinical Alzheimer's Disease Development". The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults. The investigators will compare the functional connectivity results after taking AGB101 or p...
What is the current status of trial NCT03461861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-04-11. Estimated completion is 2021-03-31.
What conditions does trial NCT03461861 study?
This clinical trial studies the following conditions: Apoe 4.
What interventions are being tested in trial NCT03461861?
The interventions under investigation include: Placebo (OTHER), AGB101 220 mg (DRUG).
Who is sponsoring clinical trial NCT03461861?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03461861 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03461861's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI